Background. Neoadjuvant chemotherapy (NAC) is used to convert patients with inoperable locally advanced breast cancer (LABC) to operability, but has not traditionally been used to avoid mastectomy or axillary dissection in this subset.
Neoadjuvant chemotherapy (NAC) is increasingly used in patients with operable breast cancer to allow more limited surgery in the breast and axilla, [1] [2] [3] with reported pathologic complete response (pCR) rates of 33-37% in the breast and 40-49% in the nodes. 2, 4 Patients presenting with locally advanced breast cancer (LABC), defined as disease in the breast with skin or chest wall involvement (cT4) and/or extensive disease in the nodes (cN2/N3), have not been considered candidates for surgical downstaging with NAC due to their heavy disease burden at presentation, although NAC is used in this group to render inoperable disease operable. These patients have traditionally been treated with modified radical mastectomy, as long-term local and regional control rates with more limited surgery are largely unknown, 5 and the accuracy of sentinel node mapping is also uncertain. 6, 7 In addition, the magnitude of benefit of modern NAC in LABC patients is also uncertain. Studies evaluating response rates are primarily limited to patients with cT4 disease, with a paucity of data in cN2 and cN3 patients. In a pooled analysis of 12 neoadjuvant trials, Cortazar et al. demonstrated overall pCR rates of 14.5 and 16% in T4a-c (n = 781) and T4d (n = 482) patients, respectively; 8 however, these pCR rates may be an underestimate, as studies were comprised of heterogenous patient populations and therapies were not targeted to a specific tumor subtype. Understanding the rates of overall, breast, and nodal pCR in patients with LABC becomes increasingly important given the success of NAC in operable breast cancer patients in improving the rates of breast-conserving surgery in borderline conservation candidates 3 and reducing the need for axillary lymph node dissection (ALND) in clinically node-positive patients, 2 particularly in those with HER2? disease. The impact of tumor burden at presentation on pCR rates is uncertain, and adoption of more limited surgery in patients with LABC could be considered if pCR rates are similar to those seen in non-LABC patients. The purpose of this study was to determine overall, breast, and nodal pCR rates in patients with LABC, and to identify factors predictive of pCR.
METHODS
Following Institutional Review Board approval, patients with locally advanced cancer, defined as disease in the breast with skin or chest wall involvement (cT4), or extensive disease in the regional lymph nodes (cN2/N3), were identified from our institutional database. LABC patients who had NAC followed by surgery at Memorial Sloan Kettering Cancer Center (MSKCC) between September 2006 and May 2016 comprised the study cohort. Patients diagnosed with distant metastatic disease prior to surgery or who did not have surgery at MSKCC were excluded. Clinicopathologic and treatment data were collected from the patient's medical record. Hormone receptor (HR) positivity was defined as [1% of cells staining positive for estrogen or progesterone receptor, and HER2 receptor was considered positive with immunohistochemical staining of 3?, or fluorescence in situ hybridization that was amplified.
The primary endpoint was overall pCR defined as no residual invasive disease in the breast and lymph nodes (in situ disease allowed). 8 Patients who presented with an occult primary breast cancer (n = 8) were excluded from the breast pCR endpoint calculation, and patients who were clinically node negative (n = 11) at presentation were excluded from the nodal pCR endpoint calculation.
Overall rates of breast and nodal pCR, as well as rates stratified by subtype, were compared using robust standard error estimates to account for correlation between paired observations and to allow for some pairs with missing data, which can occur when a patient was not eligible for analysis of both the breast and nodal pCR endpoint. All other univariable comparisons were performed using the Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical variables. Multivariable analyses of associations with pCR were conducted using logistic regression models. A p value \0.05 was considered statistically significant. All statistical analyses were conducted using R software, version 3.2.5 (R Core Development Team, Vienna, Austria).
RESULTS
Between September 2006 and May 2016, 1522 patients received NAC followed by surgery; 321 patients had locally advanced disease in the breast (cT4) and/or nodes (cN2/N3). Two hundred and sixty patients had advanced disease in either the breast or axilla, while 61 patients had advanced disease in both. Clinicopathologic and treatment characteristics are summarized in Table 1 . Overall, 223 patients had cT4 disease, 77 had cN2 disease, and 82 had cN3 disease. Median age was 52 years and median tumor size was 6 cm. Eighty-six percent of patients had ductal histology, 43% were HR positive/human epidermal growth factor receptor 2 (HER2) negative (HR?/HER2-), 23% were triple negative, and 34% were HER2?. The majority of patients (85%) were treated with mastectomy, and all patients had an ALND. The most common chemotherapy regimen was doxorubicin, cyclophosphamide, and a taxane, received by 85% of patients. All HER2? patients received HER2 targeted therapy, with 29% treated with dual anti-HER2 therapy with trastuzumab and pertuzumab ( Table 2) .
The overall pCR rate was 25% and differed significantly by receptor subtype (HR?/HER2-7%, triple negative 23%, HER2? 48%; p \ 0.001). Age, tumor size, histology, clinical T stage, and clinical N stage were not significantly associated with pCR (Table 1) . On multivariable analysis, after adjusting for clinicopathologic factors selected a priori, receptor subtype remained the only significant predictor of overall pCR, with HER2? cancers having increased odds of pCR (odds ratio [OR], HER2? 11.52, 95% confidence interval (CI) 5.25-25.1) compared with HR?/HER2-tumors (p \ 0.001) [ Table 3 ].
Breast pCR occurred in 27% of patients and was similar in T4 (n = 223) and non-T4 (n = 90) disease (29% vs. 22%; p = 0.26). Among clinically node-positive patients (n = 310), nodal pCR was achieved in 38%, with similar nodal pCR rates in patients with cN1 (43%) and cN2 (36%) or cN3 (32%) disease (p = 0.23). Nodal pCR was significantly more common than breast pCR (p = 0.014), and this was true across all tumor subtypes (Table 4 ).
In the subset of patients with inflammatory breast cancer (T4d, n = 131), overall pCR rates were 33% in T4d patients, compared with 20% in those with non-inflammatory T4 disease (n = 92; p = 0.033), while breast pCR rates were 35 and 21%, respectively (p = 0.024). Notably, T4d and non-inflammatory T4 patients differed in subtype frequency (p = 0.001), such that T4d patients were more likely to be HER2? than non-inflammatory T4 breast cancer patients (50% vs. 25%). After adjusting for receptor subtype, the association between inflammatory breast cancer and overall pCR was no longer significant (p = 0.52) [ Table 5 ].
DISCUSSION
NAC in LABC patients has traditionally been used to improve resectability, without altering surgical treatment recommendations. The National Comprehensive Cancer Network guidelines still advise modified radical mastectomy for most patients with LABC following preoperative systemic therapy, with consideration of breast-conserving surgery in a select group of patients with non-inflammatory T4 disease and a complete response after NAC. 9 However, the success of NAC in allowing more limited surgery in the breast and axilla in patients with operable breast cancer [1] [2] [3] raises the possibility that LABC patients could similarly be considered for surgical downstaging, provided that the pCR rates between early-stage and advanced cancers are comparable.
Improvements in systemic therapy and targeted therapies have improved overall pCR rates in operable breast cancer patients; early neoadjuvant trials reported pCR rates of 13% with four cycles of doxorubicin and cyclophosphamide (AC), 3 which improved to 24-28% in more recent studies with the addition of a taxane (T) to AC. 2, 4, 10 In our patient cohort of LABC patients, of whom 85% were treated with AC-T, we observed a similar overall pCR rate of 25%, suggesting that a tumor's drug sensitivity is far more important than the initial tumor burden.
As expected, receptor subtype was the most important predictor of pCR on univariable and multivariable analysis (p \ 0.001). Increasing tumor burden in the breast and regional nodes had no impact on overall, breast, or nodal pCR. HER2? patients had the highest rates of pCR (48%), similar to the 45% pCR rates seen in early-stage HER2? breast cancer patients enrolled in ACOSOG Z1071. 11 Contributing to the high pCR rate observed in HER2? patients was the use of dual anti-HER2 therapy with trastuzumab and Excludes patients who were cN0 at presentation (n = 11) pertuzumab in addition to chemotherapy in 29% of our patients. In two neoadjuvant trials, the use of dual HER2 blockade has been demonstrated to almost double the pCR rate compared with treatment with trastuzumab monotherapy, 12, 13 emphasizing the importance of optimal systemic and targeted therapy to achieve maximal treatment response.
Our data also demonstrate that breast pCR rates do not differ significantly based on tumor burden in the breast, with similar breast pCR rates observed in T4 (29%) and non-T4 (22%; p = 0.26) disease, suggesting that surgical downstaging in select patients may be feasible. However, it is unknown whether local control with breast-conserving surgery is equivalent to mastectomy in this population. Studies evaluating long-term outcomes in T4 patients undergoing breast-conserving surgery after NAC are limited. Shen et al. reported on 33 patients with T4 breast cancer treated with NAC followed by lumpectomy and radiation therapy; complete resolution of skin changes occurred in 29 patients, and the 5-year local recurrence rate was 6%.
14 In a more recent study, Murphy et al. reported surgical management and outcomes in a contemporary cohort of 98 T4 patients; 85 patients had conventional mastectomy, while 13 had either skin-sparing mastectomy (n = 9) or breast-conserving surgery (n = 4), with no difference in breast cancer-specific survival between patients receiving standard surgical therapy compared with non-standard surgical therapy (p = 0.24). 15 When considering surgical downstaging in the breast in patients with LABC, there are important considerations. One is the optimal volume of tissue to be excised. Although we know from trials in operable cancer patients that removal of the entire original tumor volume is not needed after NAC to optimize local control, 16 it is uncertain how this translates to patients with a heavier, more diffuse disease burden at presentation. Radiologic determination of pCR has a positive predictive value of 47-73%, 17 and, unlike the situation of a patient with a large unifocal tumor who downstages to breast conservation where residual disease is likely to be within the radiation boost volume, the same is not true for diffuse T4 lesions. For these reasons, initial trials of breast conservation in patients presenting with T4 lesions should be limited to patient subgroups with the highest response rates to NAC. In our study, patients with HER2? tumors had a breast Multivariable analysis includes patients with complete data for all clinicopathologic factors (n = 313) pCR rate that exceeded 50%. The exquisite sensitivity of HER2? tumors to NAC and targeted therapy, combined with the administration of additional anti-HER2 therapy postoperatively, makes them ideal candidates for future trials of surgical downstaging. At present, mastectomy remains the standard of care for diffuse T4 lesions, particularly inflammatory cancer, and attempts at breast conservation in patients with diffuse T4 disease should not be considered outside of a well-designed clinical trial. In our cohort, nodal pCR was achieved in 38% of nodepositive patients, and was more common than breast pCR, a trend also observed in patients with early-stage cancer. 2 Similar to the breast, where tumor burden did not impact pCR, we saw no difference in nodal pCR based on nodal burden at presentation (p = 0.23); nodal pCR rates in cN2 and cN3 patients were 36 and 32%, respectively. Similarly, Boughey et al. observed a 46% nodal pCR rate among 26 women with cN2 disease enrolled in ACOSOG Z1071, 4 raising the question as to whether sentinel lymph node biopsy (SLNB) can be considered in LABC patients who have a complete clinical response in the nodes after NAC. In cN1 patients, three recently published, single-arm, prospective studies have demonstrated that SLNB is accurate after NAC, with a false-negative rate of \10% provided that three or more negative SLNs are removed. 11, 18, 19 Data on the feasibility of SLNB after NAC in patients presenting with LABC are limited. Among 26 women with cN2 disease in ACOSOG Z1071 with at least two SLNs removed, the false-negative rate of SLNB in the 14 patients with residual nodal disease was 0% (95% CI 0-23.2%). 11 These numbers are promising but are too small to draw definitive conclusions from regarding the accuracy of SLNB for cN2 disease. To the best of our knowledge, studies evaluating the feasibility of SLNB in 20 Although these results are promising, the safety of lesser surgery in the axilla after NAC in clinically node-positive patients remains uncertain, and the ultimate utility of this approach in LABC patients can only be determined in a clinical trial.
CONCLUSION
Overall pCR rates in patients with LABC are comparable with those seen in early-stage breast cancer, suggesting that sensitivity to chemotherapy is not a function of tumor burden. Tumor biology, but not extent of disease, predicts pCR. Substantial pCR rates in the breast and axilla suggest that select LABC patients with an excellent response to NAC may be considered for clinical trials of surgical downstaging in the future.
DISCLOSURES The preparation of this study was funded in part by NIH/NCI Cancer Center Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center, and was presented as a poster presentation at the 70th Society of Surgical Oncology Annual Cancer Symposium, 15-18 March, 2017, Seattle, WA, USA. This study was supported by Judy Guitelman, Dan Epstein, and the Daniel J. Epstein Family Foundation. Lori F. Gentile, George Plitas, Emily C. Zabor, Michelle Stempel, Monica Morrow, and Andrea V. Barrio have no conflict of interest disclosures to report.
